"Section 232" national security levies won't apply to a wide array of drugs, meaning the "overall threat to the sector should ...
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell ...
Tyvaso, a marketed PAH therapy from United Therapeutics, continued to show potential in another lung condition. Elsewhere, ...
In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help ...
Foundayo could erase the Wegovy pill’s four-month head start as the two drugmakers clash on a debate of efficacy and ...
Colorado drugmaker Ambrosia Biosciences has landed $100 million to pursue an oral obesity drug it’s hoping can compete with a ...
The trial is tied to a post-marketing commitment that FDA Commissioner Martin Makary put in place last year for all approved ...
Constant leadership changes and erratic decision-making have left the biopharmaceutical industry feeling its chief regulator ...
A series of controversial policy changes directed by the HHS secretary have left experts fearful of the future implications ...
Chief Financial Officer Robin Kramer explained how the deal not only provides two marketed products, but a team with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results